Pharmafile Logo
Pharmafocus logo
Advanced Search

Boehringer Ingelheim

Showing 15 posts of 116 posts found.

BI building

Boehringer and BioMed X crowdsource top scientists to fight COPD

September 23, 2015
Research and Development Boehringer Ingelheim, COPD

Boehringer Ingelheim and BioMed X have used a crowdsourcing strategy to establish a global research team to collaborate on the …

News
Jardiance

More positive CV data for Boehringer and Lilly’s Jardiance

September 21, 2015
Research and Development, Sales and Marketing Boehringer Ingelheim, EASD, Eli Lilly, cardiovascular risk, empagliflozin, jardiance, mortality risk, type 2 diabetes

Jardiance, an anti-diabetes drug produced by Boehringer Ingelheim and Eli Lilly, reduces the risk of death in people with type …

News
ofev1

Boehringer earns NICE nod for IPF drug Ofev

September 14, 2015
Sales and Marketing Boehringer Ingelheim, IPF, NICE, idiopathic pulmonary fibrosis

NICE has recommended Boehringer Ingelheim’s Ofev as a treatment for idiopathic pulmonary fibrosis after the German firm agreed to a …

News
boehringer_lilly

New Boehringer and Lilly type 2 diabetes treatment gets FDA nod

August 28, 2015
Research and Development, Sales and Marketing Boehringer Ingelheim, Eli Lilly, FDA, Synjardy, type 2 diabetes

The FDA has approved Synjardy, from Boehringer Ingelheim and Eli Lilly, for the treatment of adults with type 2 diabetes. …

News
Abasaglar

Lilly and Boehringer launch biosimilar insulin in the UK

August 26, 2015
Manufacturing and Production, Research and Development, Sales and Marketing Boehringer, Boehringer Ingelheim, Eli Lilly, Lantus, abasaglar, basal insulin, biosimilar, biosimilars, diabetes, insuling glargine, lilly

Lilly and Boehringer Ingelheim have launched their biosimilar insulin, called abasaglar, for the UK market. Abasaglar will now challenge the …

News
lilly_corporate_hq

Lilly and Boehringer’s Jardiance diabetes drug reduces cardiovascular risks

August 21, 2015
Medical Communications, Research and Development Boehringer Ingelheim, Eli Lilly, diabetes drugs

Eli Lilly’s diabetes drug Jardiance (empagliflozin) has shown in a study to be the very first blood sugar lowering drug …

News
BI building

Boehringer Ingelheim launches Spiolto for COPD

July 2, 2015
Sales and Marketing Boehringer Ingelheim, COPD, Europe, Spiolto, Spiriva, Striverdi

Boehringer Ingelheim is beginning a new push in lung disease across Europe after being approved by regulators in nine countries …

News

Boehringer and Vitae Pharma drug fails in mid-stage trial

July 1, 2015
Research and Development BI, Boehringer, Boehringer Ingelheim, Vitae Pharmaceuticals, diabetes, type 2 diabetes

A pipeline diabetes drug co-developed by Vitae Pharma and German giants Boehringer Ingelheim has failed to show benefits in a …

News
Boehringer image

Boehringer Ingelheim and Bayer ‘taking the lead’ in social media

April 22, 2015
Medical Communications, Sales and Marketing Bayer, Boehringer Ingelheim, J&J and Merck, Novartis, Ogilvy Healthworld

Pharma may be finally embracing social media as a vehicle for engaging with doctors and patients, after posting more than …

News
Boehringer image

Boehringer chases approval for anti-Pradaxa drug

March 3, 2015
Sales and Marketing Boehringer, Boehringer Ingelheim, Pradaxa, bleeding, dabigatran etexilate, idarucizumab

Boehringer Ingelheim is launching new drug applications for its investigational treatment to reverse the effects of its blood-thinning drug Pradaxa. …

News
Perrigo image

Perrigo acquires Omega for $4.5 billion

November 7, 2014
Manufacturing and Production, Sales and Marketing Actavis, Boehringer Ingelheim, Boehringer Ingelheim., Elan, Perrigo, Sanofi, omega

In a deal worth $4.5 billion Perrigo has announced the acquisition of over-the-counter (OTC) drugmaker Omega. This places the Irish …

News
boehringer_angle_22

Boehringer pays $600m for cancer vaccine deal

September 19, 2014
Research and Development, Sales and Marketing Boehringer Ingelheim, cancer vaccine, oncology, pd1

Boehringer is hoping to expand its oncology pipeline with a new multi-million dollar pact for an investigational cancer vaccine. The …

News

Boehringer and InterMune data on IPF drugs impress

May 19, 2014
Research and Development, Sales and Marketing Boehringer Ingelheim, InterMune, idiopathic pulmonary fibrosis

Two new medicines for a generally fatal lung disease, known as idiopathic pulmonary fibrosis and made by Boehringer and InterMune, …

News

New managing director for Boehringer Ingelheim UK

January 13, 2014
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Boehringer Ingelheim, krumins

Zinta Krumins has been appointed as the managing director of Boehringer Ingelheim UK & Ireland. The appointment will present a …

Appointment

BI leukaemia drug gains FDA breakthrough status

September 18, 2013
Research and Development, Sales and Marketing Boehringer Ingelheim, FDA, acute myeloid leukaemia, breakthrough status

News
The Gateway to Local Adoption Series

Latest content

Rhythm AI’s STAR Apollo system receives FDA clearance for atrial fibrillation

February 12, 2026

iOrganBio appoints Karol Jarzabek as Chief Operating Officer

February 12, 2026

Ensera Design expands UK leadership team with new senior appointments

February 11, 2026

Infinitopes announces $15.4m in additional seed funding to advance cancer vaccine

February 11, 2026

Angelini Pharma appoints Roberto Scrivo as Chief of External Affairs, Communication and Sustainability Officer

February 10, 2026